Soft Tissue Repair 18.0
17.0
1. Cytori Therapeutics develops regenerative cell therapy technology using adipose-derived stem cells.
2. Its Celution system processes liposuctioned fat tissue to provide a "cell-enriched graft" containing regenerative cells for soft tissue repair and cardiovascular applications.
3. Clinical trial results show the Celution system is safe and effective for breast reconstruction, with high patient and physician satisfaction rates, supporting reimbursement efforts. A cardiovascular trial also shows improved oxygen uptake post-treatment.
Dr. Alex Milstein, VP of Clinical at Cytori presents on the Acute Injury Technology Panel at the Cardiovascular Research Foundation's Conference on Cell Therapy for Cardiovascular Disease on January 25, 2012
Cytori CEO Chris Calhoun presents as part of the "Cardiovascular, AMI & PAD" panel on the Regenerative Medicine Insight Track at the Biotech Showcase on January 10, 2012
CYTX 6th International Conference on Cell Therapy for Cardiovascular Disease ...Cytori Therapeutics, Inc.
Presented by Brad Conlan, Director of Regenerative Medicine on Thursday, January 20 at a Product Development Panel at the 6th International Conference on Cell Therapy for Cardiovascular Disease
Welcome to the first live UiPath Community Day Dubai! Join us for this unique occasion to meet our local and global UiPath Community and leaders. You will get a full view of the MEA region's automation landscape and the AI Powered automation technology capabilities of UiPath. Also, hosted by our local partners Marc Ellis, you will enjoy a half-day packed with industry insights and automation peers networking.
📕 Curious on our agenda? Wait no more!
10:00 Welcome note - UiPath Community in Dubai
Lovely Sinha, UiPath Community Chapter Leader, UiPath MVPx3, Hyper-automation Consultant, First Abu Dhabi Bank
10:20 A UiPath cross-region MEA overview
Ashraf El Zarka, VP and Managing Director MEA, UiPath
10:35: Customer Success Journey
Deepthi Deepak, Head of Intelligent Automation CoE, First Abu Dhabi Bank
11:15 The UiPath approach to GenAI with our three principles: improve accuracy, supercharge productivity, and automate more
Boris Krumrey, Global VP, Automation Innovation, UiPath
12:15 To discover how Marc Ellis leverages tech-driven solutions in recruitment and managed services.
Brendan Lingam, Director of Sales and Business Development, Marc Ellis
Dr. Alex Milstein, VP of Clinical at Cytori presents on the Acute Injury Technology Panel at the Cardiovascular Research Foundation's Conference on Cell Therapy for Cardiovascular Disease on January 25, 2012
Cytori CEO Chris Calhoun presents as part of the "Cardiovascular, AMI & PAD" panel on the Regenerative Medicine Insight Track at the Biotech Showcase on January 10, 2012
CYTX 6th International Conference on Cell Therapy for Cardiovascular Disease ...Cytori Therapeutics, Inc.
Presented by Brad Conlan, Director of Regenerative Medicine on Thursday, January 20 at a Product Development Panel at the 6th International Conference on Cell Therapy for Cardiovascular Disease
Welcome to the first live UiPath Community Day Dubai! Join us for this unique occasion to meet our local and global UiPath Community and leaders. You will get a full view of the MEA region's automation landscape and the AI Powered automation technology capabilities of UiPath. Also, hosted by our local partners Marc Ellis, you will enjoy a half-day packed with industry insights and automation peers networking.
📕 Curious on our agenda? Wait no more!
10:00 Welcome note - UiPath Community in Dubai
Lovely Sinha, UiPath Community Chapter Leader, UiPath MVPx3, Hyper-automation Consultant, First Abu Dhabi Bank
10:20 A UiPath cross-region MEA overview
Ashraf El Zarka, VP and Managing Director MEA, UiPath
10:35: Customer Success Journey
Deepthi Deepak, Head of Intelligent Automation CoE, First Abu Dhabi Bank
11:15 The UiPath approach to GenAI with our three principles: improve accuracy, supercharge productivity, and automate more
Boris Krumrey, Global VP, Automation Innovation, UiPath
12:15 To discover how Marc Ellis leverages tech-driven solutions in recruitment and managed services.
Brendan Lingam, Director of Sales and Business Development, Marc Ellis
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...SOFTTECHHUB
The choice of an operating system plays a pivotal role in shaping our computing experience. For decades, Microsoft's Windows has dominated the market, offering a familiar and widely adopted platform for personal and professional use. However, as technological advancements continue to push the boundaries of innovation, alternative operating systems have emerged, challenging the status quo and offering users a fresh perspective on computing.
One such alternative that has garnered significant attention and acclaim is Nitrux Linux 3.5.0, a sleek, powerful, and user-friendly Linux distribution that promises to redefine the way we interact with our devices. With its focus on performance, security, and customization, Nitrux Linux presents a compelling case for those seeking to break free from the constraints of proprietary software and embrace the freedom and flexibility of open-source computing.
Elevating Tactical DDD Patterns Through Object CalisthenicsDorra BARTAGUIZ
After immersing yourself in the blue book and its red counterpart, attending DDD-focused conferences, and applying tactical patterns, you're left with a crucial question: How do I ensure my design is effective? Tactical patterns within Domain-Driven Design (DDD) serve as guiding principles for creating clear and manageable domain models. However, achieving success with these patterns requires additional guidance. Interestingly, we've observed that a set of constraints initially designed for training purposes remarkably aligns with effective pattern implementation, offering a more ‘mechanical’ approach. Let's explore together how Object Calisthenics can elevate the design of your tactical DDD patterns, offering concrete help for those venturing into DDD for the first time!
The Metaverse and AI: how can decision-makers harness the Metaverse for their...Jen Stirrup
The Metaverse is popularized in science fiction, and now it is becoming closer to being a part of our daily lives through the use of social media and shopping companies. How can businesses survive in a world where Artificial Intelligence is becoming the present as well as the future of technology, and how does the Metaverse fit into business strategy when futurist ideas are developing into reality at accelerated rates? How do we do this when our data isn't up to scratch? How can we move towards success with our data so we are set up for the Metaverse when it arrives?
How can you help your company evolve, adapt, and succeed using Artificial Intelligence and the Metaverse to stay ahead of the competition? What are the potential issues, complications, and benefits that these technologies could bring to us and our organizations? In this session, Jen Stirrup will explain how to start thinking about these technologies as an organisation.
Generative AI Deep Dive: Advancing from Proof of Concept to ProductionAggregage
Join Maher Hanafi, VP of Engineering at Betterworks, in this new session where he'll share a practical framework to transform Gen AI prototypes into impactful products! He'll delve into the complexities of data collection and management, model selection and optimization, and ensuring security, scalability, and responsible use.
Accelerate your Kubernetes clusters with Varnish CachingThijs Feryn
A presentation about the usage and availability of Varnish on Kubernetes. This talk explores the capabilities of Varnish caching and shows how to use the Varnish Helm chart to deploy it to Kubernetes.
This presentation was delivered at K8SUG Singapore. See https://feryn.eu/presentations/accelerate-your-kubernetes-clusters-with-varnish-caching-k8sug-singapore-28-2024 for more details.
Epistemic Interaction - tuning interfaces to provide information for AI supportAlan Dix
Paper presented at SYNERGY workshop at AVI 2024, Genoa, Italy. 3rd June 2024
https://alandix.com/academic/papers/synergy2024-epistemic/
As machine learning integrates deeper into human-computer interactions, the concept of epistemic interaction emerges, aiming to refine these interactions to enhance system adaptability. This approach encourages minor, intentional adjustments in user behaviour to enrich the data available for system learning. This paper introduces epistemic interaction within the context of human-system communication, illustrating how deliberate interaction design can improve system understanding and adaptation. Through concrete examples, we demonstrate the potential of epistemic interaction to significantly advance human-computer interaction by leveraging intuitive human communication strategies to inform system design and functionality, offering a novel pathway for enriching user-system engagements.
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
Enhancing Performance with Globus and the Science DMZGlobus
ESnet has led the way in helping national facilities—and many other institutions in the research community—configure Science DMZs and troubleshoot network issues to maximize data transfer performance. In this talk we will present a summary of approaches and tips for getting the most out of your network infrastructure using Globus Connect Server.
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfPaige Cruz
Monitoring and observability aren’t traditionally found in software curriculums and many of us cobble this knowledge together from whatever vendor or ecosystem we were first introduced to and whatever is a part of your current company’s observability stack.
While the dev and ops silo continues to crumble….many organizations still relegate monitoring & observability as the purview of ops, infra and SRE teams. This is a mistake - achieving a highly observable system requires collaboration up and down the stack.
I, a former op, would like to extend an invitation to all application developers to join the observability party will share these foundational concepts to build on:
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
Stem Cell Meeting on the Mesa 2011: CYTX Presentation
1. Cytori Therapeutics
(NASDAQ: CYTX)
Stem Cell Meeting on the Mesa
December 1, 2011
Doug Arm, Ph.D
Sr. VP, Operations
1
2. Safe Harbor Statement
This presentation may contain certain ‘forward-looking statements’. All
statements, other than statements of historical fact, that address activities,
events or developments that we intend, expect, project, believe or
anticipate will or may occur in the future are forward-looking statements.
Such statements are based upon certain assumptions and assessments
made by our management in light of their experience and their perception
of historical trends, current conditions, expected future developments and
other factors they believe to be appropriate.
The forward-looking statements included in this presentation are also subject
to a number of material risks and uncertainties. We caution investors not to
place undue reliance on the forward-looking statements contained in this
presentation.
We would advise reading our annual report filed with the United States
Securities and Exchange Commission on Form 10-K for a more detailed
description of these risks.
2
3. Our Mission
To improve the quality and length of life
by providing innovative cell therapy for patients
3
4. Technology
Regenerative cells in the operating room in real-time
Soft Tissue Repair
About one hour
Cytori Celution® System Regenerative cells
Cardiovascular Disease
• Celution currently approved in Europe
• Scalable platform
• System/Consumable model
• 35+ issued patents
4
6. Adipose Tissue: Ideal Source for Cell Therapy
Implication: Real-time access to a patient’s own regenerative cells is possible
(No lengthy and expensive cell culture or manufacturing involved)
45 0.5
30
0.25
15
0 0
Multipotent Cells in Adipose
Total Nucleated Cells in Adipose
Multipotent Cells in BM
Number of Cells (millions) per 100 mL of tissue (1/2 cup)
6
7. Multiple Mechanisms at Work
Wound remodeling
Differentiation
Blood
Supply
Paracrine
signaling
Prevention of
cell death
Immune-
modulation
7
8. Intellectual Property: Foundation for Protection
30+ Patents Issued Worldwide with 100 + Pending
North America/Europe Asia Emerging Markets
US: Korea: Australia:
CELUTION DEVICE (‘484) CELUTION DEVICE (‘995) CELUTION DEVICE (‘135)
CELUTION PLUS ADDITIVES (‘420) STEMSOURCE DEVICE (‘812) STEMSOURCE DEVICE (‘901)
CELUTION FOR CRS (‘488) CELUTION DEVICE (‘139) CELUTION FOR CARDIOVASCULAR (‘858)
STEMSOURCE DEVICE (‘115) CELUTION DEVICE WITH CENTRIFUGE OR
CELUTION FUTURE GENERATIONS (‘075) Singapore: FILTER (‘937)
CELUTION PLUS SENSORS FOR CLINICALLY SAFE OUTPUT CELUTION DEVICE & FUTURE GENERATIONS
(‘670) South Africa:
(‘683)
CELUTION FOR BONE (‘043) CELUTION FOR CARDIOVASCULAR (‘446)
CELUTION FOR CARDIOVASCULAR (‘590)
CELUTION OR CELGRAFT FOR SOFT TISSUE DEFECTS
(‘684) Mexico:
China: CELUTION FUTURE GENERATIONS (‘348)
BEDSIDE COMPREHENSIVE CELUTION DEVICE (‘689)
DEVICE (‘059) CELUTION FOR CARDIOVASCULAR (‘775)
CELUTION FOR
CELUTION OUTPUT PLUS PROSTHETIC CARDIOVASCULAR (‘104)
FOR BONE RELATED DISORDERS (‘716)
Russia:
CELLS PLUS FAT PLUS ADDITIVES (‘795) CELUTION FOR CARDIOVASCULAR (‘924)
Japan:
CELLS PLUS FAT (‘672)
CELUTION DEVICE (‘952) India:
DEVICES FOR CELLS PLUS FAT (‘041) CELUTION DEVICE (‘706)
Europe: CLINICALLY SAFE (‘556) CELUTION FUTURE GENERATIONS (‘529)
CELUTION FOR ACUTE CELUTION DEVICE FOR TREATING WOUND
TUBULAR NECROSIS (‘834) HEALING (‘580)
Israel:
CELUTION DEVICE WITH CENTRIFUGE OR
FILTER (‘800)
8
10. Soft Tissue Repair: RESTORE Procedure
Celution® approved in EU for breast reconstruction
Significant unmet medical need $73
Two completed clinical trials $126 $163
Safe and effective
Soft Tissue Repair
Soft Tissue Repair Clinical
Soft Tissue Repair
Reimbursable
Soft Tissue Repair Partner
‘Cell-Enriched
$43 Graft’
Cells Fat
10
11. Soft Tissue Repair: RESTORE 2 Trial Outcomes
High satisfaction rates & safety to support reimbursement efforts
$73
$126
100%
Soft Tissue Repair 6-Mo
Soft Tissue Repair
Soft Tissue Repair 80%
Soft Tissue Repair 12-Mo
60%
40%
20%
0%
Patient Satisfaction
Physician
Post-Marketing Study Design Satisfaction
• Prospective 71 patient study
Co-Primary Endpoints
• Physicians and patient satisfaction with functional and cosmetic results &improvement in overall breast deformity
11
12. Cardiovascular Disease
Dr. Fernandez-Aviles
Principal Investigator
for the PRECISE trial
Hosp. Gregorio Maranon
Madrid, Spain
12
13. Cardiac Repair: PRECISE CMI Trial
Change in Max Volume of Oxygen (MV02) from Baseline to 6 & 18 months
20.0
Soft Tissue Repair 19.0
Soft Tissue Repair
Soft Tissue Repair P<0.05 P<0.05
18.0
17.2 17.1
16.0 16.6
15.5 15.3
14.0 Transplant List
N = 27 pts
(6 placebo/21 treated)
ADRC’s Baseline 6 Mos 18 Mos
Standard of Care 13
14. Cardiac Repair: PRECISE CMI Trial
28 Month Mortality Rate
Treated 5%
Placebo 33%
MVO2:significant change at 18 months
• MVO2 correlates to improved survival
• MVO2 ≤ 14 = 47% 1 yr survival rate 0% 10% 20% 30% 40%
METS: significant change at 18 months
Next Steps:
Cytori procedure safe and feasible through
18-months
Applying for European Approval
Lower cardiac mortality rate:
• At avg. follow up of 28 months: Initiating US IDE Clinical Trial: ATHENA
- 2/6 placebo
- 1/21 treated
• Completed pre-IDE meeting with FDA
14
15. Cardiac Repair: U.S. CMI Trial
Confirmed device designation by FDA
Pursuing IDE/PMA clinical trial
Pre-IDE meeting with FDA Q3 2011
Proposed design for “ATHENA” trial:
• Approx. 50 patient pilot
• Randomized, double-blind, placebo-controlled
• 1o Endpoints: Safety & Efficacy
Next Steps:
• Submit IDE application by end of year
• Initiate 1H 2012
15
16. Cardiac Repair: APOLLO Acute MI Trial
Potential new approach for treatment of heart attacks
Strong signals of safety & efficacy
Higher SAE rate in Controls
Initiated pivotal European clinical trial, ADVANCE
P < 0.05 for change from BL for ADRCs
P > 0.05 for change from BL for Placebo
Difference in reduction of infarct size is maintained in cell-treated patients
p<0.05 for change in infarct size for cell-treated patients at 6 and 18 months (paired t-test
comparing baseline and follow up for same patients)
16
17. Cardiac Repair: APOLLO Acute MI Trial
Lower abnormal ventricular beat rate in cell group
More significant Ventricular Arrhythmias in
placebo
Higher frequency of recordings with Ventricular
Premature Beats (VPB) in Controls
Higher number of VPBs per recording in placebo
17
19. Soft Tissue Repair: Defect Filling
Pre-Op
Post-Op 18 mo
8 cc cell-enriched fat
Single Session
Dr. Tunc Tiryaki
Istanbul, Turkey
19
20. Soft Tissue Repair: Radiation Necrosis
90% cells to circular area around sore
Exposed Sacrum
Note sig. inflammation, redness, swelling 10% cells to sore itself
Immediate Preop Intraop post-debride Intraop after Cell Tx
27 wks Post Op
25 Days Post Op 41 Days Post Op 20 wks Post Op
Dr. Akita
Nagasaki University, Japan
20
21. Cytori Platform: 3 Key Differentiators
0.5 M
0.4 M
0.3 M
0.2 M
0.1 M
0 Bone Marrow Adipose Tissue
1. Real-time therapy, 2. ‘Consumables’
No cell culture Business model
Wound Immune- Prevention Paracrine
Differentiation Angiogenesis
remodeling modulation cell death signaling
3. Multiple mechanisms, multiple opportunities
21
22. Current Commercial Business
• Revenue growth year over year
• Quarters variable
• Systems driving revenue
• EU focus on reconstruction
• Emerging markets & Asia:
- Aesthetics
- Reconstruction
- Translational research
- StemSource® cell & tissue banks
22
23. Global Cell Therapy Market
$ 3.5 B
CRS $ 5.0 B
Wounds
$ 16 B
Urology
$ 33 B
AMI
$ 200 B
Chronic Heart Failure
23